Skip to main content

Home
Browse by Topic
Special Series
Multimedia
- Video Library
- Rapid Reactions

Home
Browse by Topic
Special Series
Multimedia
- Video Library
- Rapid Reactions

The Role of Anti-PD-1 Antibodies

Clinical Commentary

Dr. Sanjiv Agarwala addresses the possibility of updating indications for Nivolumab and Pembrolizumab in the therapeutic arena.

Related Items

Hot Topics in Treating Cutaneous Malignancies

Clinical Commentary

Melanoma in Personalized Medicine and Biomarkers

Clinical Commentary

Local Regional Therapy and Surgery for Melanoma

Clinical Commentary

Dermatologists and Medical Oncologists: Working Together

Clinical Commentary

Anti-CTLA4 vs. Anti-PD-1

Clinical Commentary

A Look Into Anti-PD-1 and Anti-PD-L1 Therapies

Clinical Commentary

Pembrolizumab vs. Ipilimumab

Clinical Commentary

Targeting Multiple Pathways with Immunotherapies

Clinical Commentary

Basal Cell Carcinoma Case Studies in Hedgehog Pathway Inhibition

Clinical Commentary

The Impact of Hedgehog Pathway Inhibitors on the Management of Patients with Basal Cell Carcinoma

Clinical Commentary

Home
About
Contact Us
Subscribe

Copyright © Amplity Health. All rights reserved. Privacy Policy

First Name*

Last Name*

Email*

Country*

Address

Address (Continued)

City

State/Province

ZIP Code

I have reviewed and consent to the terms of PMO's Privacy Policy, and PMO has my permission to retain my information in its database, and to forward pertinent communications to me.

Please verify your request*